Literature DB >> 10701524

Plasma endothelin concentrations after aneurysmal subarachnoid hemorrhage.

S Juvela1.   

Abstract

OBJECT: The pathogenesis of cerebral vasospasm and delayed ischemia after subarachnoid hemorrhage (SAH) seems to be complex. An important mediator of chronic vasospasm may be endothelin (ET), with its powerful and long-lasting vasoconstricting activity. In this study the author investigated the correlation between serial plasma concentrations of ET and ischemic symptoms, angiographically demonstrated evidence of vasospasm, and computerized tomography (CT) findings after aneurysmal SAH.
METHODS: Endothelin-1 immunoreactivity in plasma was studied in 70 patients with aneurysmal SAH and in 25 healthy volunteers by using a double-antibody sandwich-enzyme immunoassay (immunometric) technique. On the whole, mean plasma ET concentrations in patients with SAH (mean +/- standard error of mean, 2.1 +/- 0.1 pg/ml) did not differ from those of healthy volunteers (1.9 +/- 0.2 pg/ml). Endothelin concentrations were significantly higher (p < 0.05) in patients who experienced delayed cerebral ischemia with fixed neurological deficits compared with those in other patients (post-SAH Days 0-5, 3.1 +/- 0.8 pg/ml compared with 2.1 +/- 0.2 pg/ml; post-SAH Days 6-14, 2.5 +/- 0.4 pg/ml compared with 1.9 +/- 0.2 pg/ml). Patients with angiographic evidence of severe vasospasm also had significantly (p < 0.05) elevated ET concentrations (post-SAH Days 0-5, 3.2 +/- 0.8 pg/ml; post-SAH Days 6-14, 2.7 +/- 0.5 pg/ml) as did those with a cerebral infarction larger than a lacuna on the follow-up CT scan (post-SAH Days 0-5, 3.1 +/- 0.8 pg/ml; post-SAH Days 6-14, 2.5 +/- 0.4 pg/ml) compared with other patients. Patients in whom angiography revealed diffuse moderate-to-severe vasospasm had significantly (p < 0.05) higher ET levels than other patients within 24 hours before or after angiography (2.6 +/- 0.3 compared with 1.9 +/- 0.2 pg/ml). In addition, patients with a history of hypertension or cigarette smoking experienced cerebral infarctions significantly more often than other patients, although angiography did not demonstrate severe or diffuse vasospasm more often in these patients than in others.
CONCLUSIONS: Endothelin concentrations seem to correlate with delayed cerebral ischemia and vasospasm after SAH. The highest levels of ET are predictive of the symptoms of cerebral ischemia and vasospasm, and ET may also worsen ischemia in patients with a history of hypertension. Thus, ET may be an important causal or contributing factor to vasospasm, but its significance in the pathogenesis of vasospasm remains unknown.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10701524     DOI: 10.3171/jns.2000.92.3.0390

Source DB:  PubMed          Journal:  J Neurosurg        ISSN: 0022-3085            Impact factor:   5.115


  25 in total

Review 1.  Cerebral artery myogenic reactivity: The next frontier in developing effective interventions for subarachnoid hemorrhage.

Authors:  Darcy Lidington; Jeffrey T Kroetsch; Steffen-Sebastian Bolz
Journal:  J Cereb Blood Flow Metab       Date:  2017-11-14       Impact factor: 6.200

2.  Statins and anti-inflammatory therapies for subarachnoid hemorrhage.

Authors:  Rajat Dhar; Michael Diringer
Journal:  Curr Treat Options Neurol       Date:  2012-04       Impact factor: 3.598

3.  Radiological scales predicting delayed cerebral ischemia in subarachnoid hemorrhage: systematic review and meta-analysis.

Authors:  Wessel E van der Steen; Eva L Leemans; René van den Berg; Yvo B W E M Roos; Henk A Marquering; Dagmar Verbaan; Charles B L M Majoie
Journal:  Neuroradiology       Date:  2019-01-28       Impact factor: 2.804

4.  Juguloarterial endothelin-1 gradients after severe traumatic brain injury.

Authors:  Doris A Chatfield; Darshan H Brahmbhatt; Tilly Sharp; Iain E Perkes; Joanne G Outrim; David K Menon
Journal:  Neurocrit Care       Date:  2011-02       Impact factor: 3.210

5.  The costs and prognostic characteristics of ischaemic neurological deficit due to subarachnoid haemorrhage in the United Kingdom. Evidence from the MRC International Subarachnoid Aneurysm Trial.

Authors:  Oliver Rivero-Arias; Jane Wolstenholme; Alastair Gray; Andrew J Molyneux; Richard S C Kerr; Julia A Yarnold; Mary Sneade
Journal:  J Neurol       Date:  2009-02-09       Impact factor: 4.849

6.  Soluble and catalytically active endothelin converting enzyme-1 is present in cerebrospinal fluid of subarachnoid hemorrhage patients.

Authors:  Sanjaya Kuruppu; Sherry H-Y Chou; Steven K Feske; Sarah Suh; Iresha Hanchapola; Eng H Lo; Mingming Ning; A Ian Smith
Journal:  Mol Cell Proteomics       Date:  2013-07-01       Impact factor: 5.911

Review 7.  Biomarkers as outcome predictors in subarachnoid hemorrhage--a systematic review.

Authors:  Caron M Hong; Cigdem Tosun; David B Kurland; Volodymyr Gerzanich; David Schreibman; J Marc Simard
Journal:  Biomarkers       Date:  2014-02-05       Impact factor: 2.658

8.  Plasma endothelin-1 as screening marker for cerebral vasospasm after subarachnoid hemorrhage.

Authors:  J Bellapart; Lee Jones; H Bandeshe; R Boots
Journal:  Neurocrit Care       Date:  2014-02       Impact factor: 3.210

9.  High-dose bosentan in the prevention and treatment of subarachnoid hemorrhage-induced cerebral vasospasm: an open-label feasibility study.

Authors:  Raul G Nogueira; Michael J Bodock; Walter J Koroshetz; Mehmet A Topcuoglu; Bob S Carter; Christopher S Ogilvy; Johnny C Pryor; Ferdinando S Buonanno
Journal:  Neurocrit Care       Date:  2007       Impact factor: 3.210

10.  Role of Cyclooxygenase-2 in Relation to Nitric Oxide and Endothelin-1 on Pathogenesis of Cerebral Vasospasm After Subarachnoid Hemorrhage in Rabbit.

Authors:  Akira Munakata; Masato Naraoka; Takeshi Katagai; Norihito Shimamura; Hiroki Ohkuma
Journal:  Transl Stroke Res       Date:  2016-04-05       Impact factor: 6.829

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.